A rare cause of salt wasting and failure to thrive in infancy: case of aldosterone synthase deficiency

Authors

  • Rose Mary Tom Department of Paediatrics, Aster MIMS, Calicut, Kerala, India
  • Dhanya Soodhana Mohan Department of Paediatric Endocrinology, Aster MIMS, Calicut, Kerala, India
  • Preetha Remesh Department of Paediatrics and Neonatology Aster MIMS, Calicut, Kerala, India
  • Anand Manjeri Ramachandran Department of Paediatrics and Neonatology Aster MIMS, Calicut, Kerala, India
  • Divya Pachat Department of Clinical Genetics, Aster MIMS, Calicut, Kerala, India

DOI:

https://doi.org/10.18203/2349-3291.ijcp20262430

Keywords:

Aldosterone synthase deficiency, CYP11B2, Salt wasting, Hyperkalemia, Hyponatremia, Failure to thrive, Congenital hypoaldosteronism

Abstract

Aldosterone synthase deficiency (ASD) is a rare autosomal recessive disorder caused by pathogenic variants in CYP11B2 that impair aldosterone biosynthesis. It presents with salt-wasting, hyponatremia, hyperkalaemia and failure to thrive in infancy and can be life‑threatening if not recognized and treated. We report an infant with early-onset salt-wasting and a novel CYP11B2 variant. A 56‑day‑old female, presented with poor weight gain and dehydration. Laboratory investigations showed hyponatremia, severe hyperkalaemia, metabolic acidosis and mildly elevated 17‑hydroxyprogesterone; cortisol and ACTH were normal. Plasma aldosterone was low (4.4 ng/dl) with low‑normal renin activity (2.39 ng/ml/h). Clinical exome sequencing identified a homozygous c.542G>C (p. Arg181Pro) likely pathogenic variant in CYP11B2, consistent with aldosterone synthase deficiency. Acute management included intravenous fluids, sodium supplementation and anti‑hyperkalemic measures. The child received empirical hydrocortisone initially and was started on fludrocortisone (200 µg/day) with oral sodium chloride supplementation. On follow‑up the infant demonstrated appropriate weight gain and normal development. ASD should be considered in infants with salt‑wasting and failure to thrive without virilization. Prompt recognition, acute electrolyte correction, and mineralocorticoid replacement lead to favourable short‑ and long‑term outcomes. Genetic testing confirms the diagnosis and enables counselling for recurrence risk.

References

Garrelfs MR, Rinne T, Hillebrand JJ, Lauffer P, Bijlsma MW, Claahsen-van der Grinten HL, et al. Identification of a novel CYP11B2 variant in a family with varying degrees of aldosterone synthase deficiency. J Clin Res Pediatr Endocrinol. 2024;16(1):95-101.

Kondo E, Nakamura A, Homma K, Hasegawa T, Yamaguchi T, Narugami M, et al. Two novel mutations of the CYP11B2 gene in a Japanese patient with aldosterone deficiency type 1. Endocr J. 2013;60(1):51-5.

Wijaya M, Ma H, Zhang J, Du M, Li Y, Chen Q, et al. Aldosterone signalling defect in young infants: single-center report and review. BMC Endocr Disord. 2021;21(1):149.

Parajes S, Loidi L, Reisch N, Dhir V, Rose IT, Hampel R, et al. Functional consequences of seven novel mutations in the CYP11B1 gene: four mutations associated with nonclassic and three mutations causing classic 11β-hydroxylase deficiency. J Clin Endocrinol Metab. 2010;95(2):779-88.

Miao H, Yu Z, Lu L, Zhu H, Auchus RJ, Liu J, et al. Analysis of novel heterozygous mutations in the CYP11B2 gene causing congenital aldosterone synthase deficiency and literature review. Steroids. 2019;150:108448.

Hui E, Yeung MCW, Cheung PT, Kwan E, Low L, Tan KCB, et al. The clinical significance of aldosterone synthase deficiency: report of a novel mutation in the CYP11B2 gene. BMC Endocr Disord. 2014;14:29.

Turan H, Dağdeviren Çakır A, Özer Y, Tarçın G, Özcabi B, Ceylaner S, et al. Clinical and genetic characteristics of patients with corticosterone methyloxidase deficiency type 2: novel mutations in CYP11B2. J Clin Res Pediatr Endocrinol. 2021;13(2):232-8.

Baudrand R, Vaidya A. The low-renin hypertension phenotype: genetics and the role of the mineralocorticoid receptor. Int J Mol Sci. 2018;19(2):546.

Wasniewska M, De Luca F, Valenzise M, Lombardo F. Aldosterone synthase deficiency type I with no documented homozygous mutations in the CYP11B2 gene. Eur J Endocrinol. 2001;144:59-62.

Løvås K, McFarlane I, Nguyen HH, Curran S, Schwabe J, Halsall D, et al. A novel CYP11B2 gene mutation in an Asian family with aldosterone synthase deficiency. J Clin Endocrinol Metab. 2009;94(3):914-9.

Yupanqui ME, Schrader-Florez C, López-Ramírez S, Valenzuela-Vallejo L, Perez-Barreto A, Céspedes Salazar C, et al. Congenital hyperreninemic hypoaldosteronism: a case report. SAGE Open Med Case Rep. 2023;11:2050313X231201724.

Ur Rehman S, Aftab S, Naseem A, Saeed A, Cheema HA. Corticosterone methyloxidase type 1 deficiency due to CYP11B2 mutation: two case reports. Cureus. 2023;15(5):e39181.

Lages AS, Vale B, Oliveira P, Cardoso R, Dinis I, Carrilho F, et al. Congenital hyperreninemic hypoaldosteronism due to aldosterone synthase deficiency type I in a Portuguese patient: case report and review of literature. Arch Endocrinol Metab. 2019;63(1):84-8.

Üstyol A, Atabek ME, Taylor N, Yeung MC, Chan AO. Corticosterone methyloxidase deficiency type 1 with normokalemia in an infant. J Clin Res Pediatr Endocrinol. 2016;8(3):356-9.

Sethupathi V, Vijayakumar M, Janakiraman L, Nammalwar BR. Congenital hypoaldosteronism. Indian Pediatr. 2008;45(8):695-7.

Kamarajan LP, Mahto M, Kumar S, Kumar P. Cracking the code of aldosterone synthase deficiency: bridging genetics and biochemistry—a case report. Lab Med. 2025;56(4):419-22.

Jessy T, Fahmeeda M, Rohini A, Edwin T. Aldosterone synthase deficiency: a case report. Int J Sci Res Pediatr. 2025;14(2):31.

Downloads

Published

2026-07-27

How to Cite

Tom, R. M., Mohan, D. S., Remesh, P., Ramachandran, A. M., & Pachat, D. (2026). A rare cause of salt wasting and failure to thrive in infancy: case of aldosterone synthase deficiency. International Journal of Contemporary Pediatrics, 13(8), 1522–1527. https://doi.org/10.18203/2349-3291.ijcp20262430

Issue

Section

Case Reports